Skyrizi

Active substance

Risankizumab

Holder

AbbVie Belgium SA/NV

Status

closed

Indication

treatment of patients with active Crohn's Disease who have no other suitable

treatment option and are not eligible to participate in a clinical study for their serious or life-threatening condition

Public documents

Approbation

Approbation amendment

Information for the patient

Informed consent

Last update

21/02/2023

Last updated on 03/04/2024